Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Georgios Schoretsanitis, Edoardo Spina, Christoph Hiemke & Jose de Leon. (2018) A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. Expert Review of Clinical Pharmacology 11:6, pages 625-639.
Read now
Read now
M. C. Mauri, A. Reggiori, S. Paletta, C. Di Pace & A. C. Altamura. (2017) Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation. Expert Opinion on Drug Safety 16:3, pages 365-379.
Read now
Read now
Kadir Demirci, Ramazan Özçankaya, H. Ramazan Yilmaz, Ayşe Yiğit, Abdülhadi Cihangir Uğuz, Kadir Karakuş, Arif Demirdaş & Abdullah Akpınar. (2015) Paliperidone regulates intracellular redox system in rat brain: Role of purine mechanism. Redox Report 20:4, pages 170-176.
Read now
Read now
Pierre S Chue, Erin M MacKenzie, James A Chue & Glen B Baker. (2012) The pharmacology and formulation of paliperidone extended release. Expert Review of Neurotherapeutics 12:12, pages 1399-1410.
Read now
Read now
Pierre Chue & James Chue. (2012) A review of paliperidone palmitate. Expert Review of Neurotherapeutics 12:12, pages 1383-1397.
Read now
Read now
Maximilian Gahr, Markus A Kölle, Carlos Schönfeldt-Lecuona, Peter Lepping & Roland W Freudenmann. (2011) Paliperidone extended-release: does it have a place in antipsychotic therapy?. Drug Design, Development and Therapy 5, pages 125-146.
Read now
Read now
Meera Narasimhan, Shilpa Srinivasan, Chi Un Pae & Prakash Masand. (2008) Profile of paliperidone extended release: review of efficacy and safety data. Expert Review of Clinical Pharmacology 1:6, pages 737-744.
Read now
Read now
Articles from other publishers (27)
Jianlin Han, Attila Márió Remete, Luca S. Dobson, Lorand Kiss, Kunisuke Izawa, Hiroki Moriwaki, Vadim A. Soloshonok & David O’Hagan. (2020) Next generation organofluorine containing blockbuster drugs. Journal of Fluorine Chemistry 239, pages 109639.
Crossref
Crossref
Habibur Rahman, S.K. Manirul Haque & Masoom Raza Siddiqui. (2020) A Comprehensive Review on Importance and Quantitation of Atypical Antipsychotic Drugs and their Active Metabolites in Commercial Dosage Forms. Current Pharmaceutical Analysis 16:8, pages 989-1019.
Crossref
Crossref
Faizan Mazhar, Carla Carnovale, Nafis Haider, Rafeeque Ahmed & Murtada Taha. (2020) Paliperidone-Associated Hyponatremia. Journal of Clinical Psychopharmacology 40:2, pages 202-205.
Crossref
Crossref
Yangang Zhou, Huande Li, Ping Xu, Li Sun, Qing Wang, Qiong Lu, Haiyan Yuan & Yiping Liu. (2018) Paliperidone, a relatively novel atypical antipsychotic drug, is a substrate for breast cancer resistance protein. Experimental and Therapeutic Medicine.
Crossref
Crossref
Larry Yet. 2018. Privileged Structures in Drug Discovery. Privileged Structures in Drug Discovery
155
193
.
Zengliu Su, Christina Overton, Frank Wallace & Gregory McIntire. (2017) Positive Urine Paliperidone Test Results in the Absence of Prescribed Medication. The Journal of Applied Laboratory Medicine 2:3, pages 436-439.
Crossref
Crossref
Daniel Bressington, Jon Stock, Sabina Hulbert & Douglas MacInnes. (2015) A retrospective observational study of the effectiveness of paliperidone palmitate on acute inpatient hospitalization rates. International Clinical Psychopharmacology 30:4, pages 230-236.
Crossref
Crossref
Rocco A. Zoccali, Antonio Bruno & Maria Rosaria Anna Muscatello. (2015) Efficacy and Safety of Sertindole in Schizophrenia. Journal of Clinical Psychopharmacology 35:3, pages 286-295.
Crossref
Crossref
Yinbo Zhang & Guangzhi Dai. (2012) Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first‐episode schizophrenia through 52 weeks follow‐up in China. Human Psychopharmacology: Clinical and Experimental 27:6, pages 605-614.
Crossref
Crossref
Nga Tran & Deirdre Alderton. 2012. Pharmacological and Psychosocial Treatments in Schizophrenia, Third Edition. Pharmacological and Psychosocial Treatments in Schizophrenia, Third Edition
1
31
.
Roberto Cavallaro, Marta Bosia, Carmelo Guglielmino & Enrico Smeraldi. (2012) 9-OH risperidone response in risperidone poor responders: An open study of drug response concordance. Neurology, Psychiatry and Brain Research 18:3, pages 109-113.
Crossref
Crossref
David J. Castle, Nga Tran & Deirdre Alderton. 2012. Pharmacological and Psychosocial Treatments in Schizophrenia. Pharmacological and Psychosocial Treatments in Schizophrenia
1
31
.
W. Wolfgang Fleischhacker, Srihari Gopal, Rosanne Lane, Cristiana Gassmann-Mayer, Pilar Lim, David Hough, Bart Remmerie & Marielle Eerdekens. (2012) A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. International Journal of Neuropsychopharmacology 15:1, pages 107-118.
Crossref
Crossref
Nikhil Nihalani, Thomas L. Schwartz, Umar A. Siddiqui & James L. Megna. (2011) Obesity and Psychotropics. CNS Neuroscience & Therapeutics 18:1, pages 57-63.
Crossref
Crossref
Edoardo Spina & Rosalia Crupi. (2011) Safety and Efficacy of Paliperidone Extended-Release in Acute and Maintenance Treatment of Schizophrenia. Journal of Central Nervous System Disease 3, pages JCNSD.S1607.
Crossref
Crossref
Nikhil Nihalani, Thomas L. Schwartz, Umar A. Siddiqui & James L. Megna. (2011) Weight Gain, Obesity, and Psychotropic Prescribing. Journal of Obesity 2011, pages 1-9.
Crossref
Crossref
Silvio Bellino, Paola Bozzatello, Camilla Rinaldi & Filippo Bogetto. (2011) Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability. Depression Research and Treatment 2011, pages 1-7.
Crossref
Crossref
Mehrul Hasnain, W. Victor R. Vieweg & Sonja K. Fredrickson. (2010) Metformin for Atypical Antipsychotic-Induced Weight Gain and Glucose Metabolism Dysregulation. CNS Drugs 24:3, pages 193-206.
Crossref
Crossref
L. Citrome. (2009) Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. International Journal of Clinical Practice 64:2, pages 216-239.
Crossref
Crossref
Jose de Leon, Gary Wynn & Neil B. Sandson. (2010) The Pharmacokinetics of Paliperidone Versus Risperidone. Psychosomatics 51:1, pages 80-88.
Crossref
Crossref
David Hough, Jean-Pierre Lindenmayer, Srihari Gopal, Rama Melkote, Pilar Lim, Virginie Herben, Eric Yuen & Marielle Eerdekens. (2009) Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 33:6, pages 1022-1031.
Crossref
Crossref
Mehrul Hasnain, W. Victor R. Vieweg, Sonja K. Fredrickson, Mary Beatty-Brooks, Antony Fernandez & Anand K. Pandurangi. (2009) Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. Primary Care Diabetes 3:1, pages 5-15.
Crossref
Crossref
Maria Geitona, Hara Kousoulakou, Markos Ollandezos, Kostas Athanasakis, Sotiria Papanicolaou & Ioannis Kyriopoulos. (2008) Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study. Annals of General Psychiatry 7:1.
Crossref
Crossref
Matthew Macaluso & Ahsan Y. Khan. (2008) A 19-year-old Black Woman with Psychotic and Depressive Symptoms. Psychiatric Annals 38:5.
Crossref
Crossref
Andrew Cutler, Sara Ball & Stephen M. Stahl. (2014) Dosing Atypical Antipsychotics. CNS Spectrums 13:S9, pages 3-14.
Crossref
Crossref
Abraham M Nussbaum & T S Stroup. (2008) Oral paliperidone for schizophrenia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Shridhar Hegde & Michelle Schmidt. 2008.
455
497
.